Literature DB >> 10893485

Novel polymorphisms of the human cholecystokinin A receptor gene: an association analysis with schizophrenia.

H Tachikawa1, S Harada, Y Kawanishi, T Okubo, H Shiraishi.   

Abstract

The cholecystokinin A receptor (CCK-AR) modulates CCK-stimulated dopamine release in the posterior nucleus accumbens, and its gene is mapped to 4p15.2-15.1 with the dopamine receptor 5 (DR5) gene. We speculated that alterations in the CCK-AR lead to an increase in dopamine release, which may in turn constitute a predisposition in schizophrenia. We investigated genetic variations in the promoter region and the coding region of the CCK-AR gene. An association analysis was conducted between 83 unrelated schizophrenic patients and 80 healthy controls. Novel polymorphisms (201A-->G, 246G-->A in the promoter region, 1260T-->A, 1266T-->C in intron 1 within the 3' mRNA splice acceptor site consensus sequence, and Leu306Leu in exon 5) were found in addition to the variants (608G-->A in intron 1, 3849C-->T [Ile296Ile] in exon 5) reported previously. Significant differences were found in the allele frequencies of the 201A-->G nucleotide substitution in the promoter region between patients and controls (P = 0.0181, odds ratio: 1.972, after Bonferroni correction: P = 0.0543). These differences were also found between the patients with paranoid type and controls (P = 0.0274, odds ratio = 3.667, after Bonferroni correction: P = 0.0822). Our analyses suggest that the 201A allele frequency was higher in the schizophrenic group, especially in the paranoid type, than in the control group at a rate that was not quite significant after Bonferroni correction. Am J. Med Genet. (Neuropsychiatr. Genet.) 96:141-145, 2000. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10893485     DOI: 10.1002/(sici)1096-8628(20000403)96:2<141::aid-ajmg3>3.0.co;2-r

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  4 in total

Review 1.  Recent advances in the genetics of schizophrenia.

Authors:  D M Waterwort; A S Bassett; L M Brzustowicz
Journal:  Cell Mol Life Sci       Date:  2002-02       Impact factor: 9.261

2.  Pharmacological evidence for putative CCK(1) receptor heterogeneity in human colon smooth muscle.

Authors:  M F Morton; E A Harper; I A Tavares; N P Shankley
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

3.  Identification of the transcriptional targets of FOXP2, a gene linked to speech and language, in developing human brain.

Authors:  Elizabeth Spiteri; Genevieve Konopka; Giovanni Coppola; Jamee Bomar; Michael Oldham; Jing Ou; Sonja C Vernes; Simon E Fisher; Bing Ren; Daniel H Geschwind
Journal:  Am J Hum Genet       Date:  2007-10-31       Impact factor: 11.025

Review 4.  Evaluating the links between schizophrenia and sleep and circadian rhythm disruption.

Authors:  David Pritchett; Katharina Wulff; Peter L Oliver; David M Bannerman; Kay E Davies; Paul J Harrison; Stuart N Peirson; Russell G Foster
Journal:  J Neural Transm (Vienna)       Date:  2012-05-10       Impact factor: 3.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.